Protagen Selected by Pfizer to Support Clinical Drug Development of a Novel Compound in Autoimmune Diseases

Tuesday, 03 December 2013

Protagen announced today that a collaboration agreement with Pfizer Inc. has been signed. Under the collaboration, Protagen will use its proprietary SeroTag process to attempt to discover prediction or patient stratification markers for a novel drug being developed by Pfizer.

Protagen CEO Stefan Müllner comments, “The current agreement shows that the SeroTag process of Protagen is relevant technology to explore novel biomarkers in support of clinical development in inflammatory and autoimmune diseases. We look forward to a productive and collaborative relationship with Pfizer's R&D team.”

About Protagen AG

PROTAGEN is a pioneer in the development of novel diagnostic products to support personalized therapies, and the clinical development of new drugs in autoimmune diseases. The unique SeroTag process addresses the unmet need to deliver specific biomarkers with clinical utility for treatment response prediction, disease activity monitoring, and companion diagnostics (CDx). SeroTag has been successfully employed for marker discovery and patient stratification in various autoimmune diseases such as RA, SLE, MS and related disorders.

Contact

Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund

Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: bd@protagen.com

Media Enquiries

Dr. Georg Lautscham
CBO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund

Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: bd@protagen.com

Contact us